[518] Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients With Advanced Fibrosis/Cirrhosis

Şimşek, Halis; Schiff, Eugene R.; Goodman, Z.; Brett‐Smith, Helena; Klesczewski, K.; Kreter, Bruce

doi:10.1016/s0168-8278(07)62116-3

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients on entecavir were more likely than lamivudine to have undetectable HBV DNA, ALT normalization, and histologic improvement [109]. The role of entecavir in decompensated disease has not been reported but expected to have better results than other nucleos(t)ide analogues because of rapid viral suppression and low resistance rate.…”

Section: Entecavir Therapy In Other Patient Subgroupsmentioning

confidence: 99%

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Leung

2008

Hepatol Int

View full text Add to dashboard Cite

Forty years ago in 1967, Professor Blumberg discovered the Australian Antigen, later known as the hepatitis B surface antigen, and was awarded the Nobel Prize. This discovery enables the diagnosis of hepatitis B virus (HBV) infection and defines its epidemiology. Viral hepatitis B infection affects global health situation, and chronic hepatitis B (CHB) is particularly serious in the Asia-Pacific region. HBV vaccines created the first breakthrough in HBV prevention. Through universal HBV vaccination program for the newborns, promoted since the mid-1980s, the main route that perpetuates chronic infection from mother to child is curbed. Most children and young adults now have immunity against HBV infection. The next breakthrough comes with therapy for CHB. This prevents progression to cirrhosis and hepatocellular carcinoma. Standard interferon therapy with modest efficacy has been largely replaced by therapy with nuclos(t)ide analogues or pegylated interferons alfa-2a and -2b. Lamivudine was approved by the FDA USA in 1998, followed by adefovir dipivoxil in 2002, entecavir in 2005, and telbivudine in 2006. Clevudine, tenofovir, and many promising candidates are in different stages of development and clinical trial. This paper critically reviews recent data published or presented since the APASL Consensus and Guideline Update of 2005. Clinical efficacy mostly in patients with raised serum alanine aminotransferase will be analyzed.

show abstract

Section: Entecavir Therapy In Other Patient Subgroupsmentioning

confidence: 99%

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Leung

2008

Hepatol Int

View full text Add to dashboard Cite

show abstract

Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients

Cheng

Chang

2008

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Entecavir has demonstrated safety and efficacy in the treatment of chronic hepatitis B infection. It is the prototype for the cyclopentane class of nucleoside/nucleotide chronic hepatitis B antiviral agents. It has a high potency and, due to its structural formula and mechanism of action, entecavir is associated with emergence of minimal resistance in the long-term treatment of nucleoside-naive patients. Research suggests that long-term treatment may be required for chronic hepatitis B patients, especially those who acquire HBV early in life, to achieve maximum viral suppression and improve outcomes. Several recent studies have evaluated the long-term safety, efficacy and development of resistance in nucleoside-naive patients treated with entecavir. Results indicate that the long-term use of entecavir is well tolerated and associated with continuous clinical improvement -- with an increasing number of patients achieving undetectable levels of HBV DNA, HBeAg seroconversion and minimal resistance. These data underscore the position of entecavir for first-line therapy and highlight its role in the long-term treatment of chronic hepatits B.

show abstract

[518] Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients With Advanced Fibrosis/Cirrhosis

Cited by 2 publications

References 0 publications

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients

Contact Info

Product

Resources

About